UA59384C2
(uk)
*
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
PT966436E
(pt)
*
|
1997-02-21 |
2003-03-31 |
Bayer Ag |
Arilsulfonamidas e analogos e sua aplicacao para o tratamento de doencas neurodegenerativas
|
ATE413386T1
(de)
*
|
1998-01-29 |
2008-11-15 |
Amgen Inc |
Ppar-gamma modulatoren
|
DE19837627A1
(de)
|
1998-08-19 |
2000-02-24 |
Bayer Ag |
Neue Aminosäureester von Arylsulfonamiden und Analoga
|
US7041691B1
(en)
*
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
DE10015866A1
(de)
|
2000-03-30 |
2001-10-11 |
Bayer Ag |
Aryl- und Heteroarylsulfonate
|
US20090124690A1
(en)
*
|
2000-04-03 |
2009-05-14 |
Alberte Randall S |
Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
|
WO2001082916A2
(en)
|
2000-05-03 |
2001-11-08 |
Tularik Inc. |
Combination therapeutic compositions and methods of use
|
US20030171399A1
(en)
*
|
2000-06-28 |
2003-09-11 |
Tularik Inc. |
Quinolinyl and benzothiazolyl modulators
|
DE10047486A1
(de)
*
|
2000-09-26 |
2002-04-11 |
Bayer Ag |
Phenoxyphenyl Alkansulfonate
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
UA75093C2
(en)
|
2000-10-06 |
2006-03-15 |
Dimensional Pharm Inc |
Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
|
GB0028702D0
(en)
*
|
2000-11-24 |
2001-01-10 |
Novartis Ag |
Organic compounds
|
AU2006200813A1
(en)
*
|
2000-11-24 |
2006-03-16 |
Novartis Ag |
Naphthalene derivatives
|
US6708906B2
(en)
*
|
2000-12-29 |
2004-03-23 |
Siemens Automotive Corporation |
Modular fuel injector having a surface treatment on an impact surface of an electromagnetic actuator and having an integral filter and dynamic adjustment assembly
|
US7507767B2
(en)
*
|
2001-02-08 |
2009-03-24 |
Schering Corporation |
Cannabinoid receptor ligands
|
AU2002319627A1
(en)
|
2001-07-20 |
2003-03-03 |
Merck And Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
WO2003061699A1
(fr)
*
|
2001-12-27 |
2003-07-31 |
Japan Tobacco, Inc. |
Remedes pour affections allergiques
|
US20040171613A1
(en)
*
|
2001-12-27 |
2004-09-02 |
Japan Tobacco Inc. |
Therapeutic agent for non-immediate type allergic diseases
|
JPWO2003070277A1
(ja)
*
|
2002-02-19 |
2005-06-09 |
塩野義製薬株式会社 |
抗掻痒剤
|
EP1487436A4
(en)
|
2002-03-08 |
2009-06-03 |
Signal Pharm Inc |
POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
|
NZ534757A
(en)
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
JP2005528366A
(ja)
|
2002-03-26 |
2005-09-22 |
メルク エンド カムパニー インコーポレーテッド |
カンナビノイド受容体モジュレータとしてのスピロ環式アミド
|
AU2003225964B2
(en)
|
2002-03-28 |
2008-11-20 |
Merck Sharp & Dohme Corp. |
Substituted 2,3-diphenyl pyridines
|
DE10215942A1
(de)
*
|
2002-04-11 |
2003-10-23 |
Bayer Ag |
Wässrige Formulierungen von (2-Hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorbutan-1-sulfonat
|
CA2481313A1
(en)
|
2002-04-12 |
2003-10-23 |
Merck & Co., Inc. |
Bicyclic amides
|
US7176322B2
(en)
|
2002-05-23 |
2007-02-13 |
Amgen Inc. |
Calcium receptor modulating agents
|
US6908935B2
(en)
|
2002-05-23 |
2005-06-21 |
Amgen Inc. |
Calcium receptor modulating agents
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
US7094789B2
(en)
|
2002-07-22 |
2006-08-22 |
Asahi Kasei Pharma Corporation |
5-substituted isoquinoline derivatives
|
EP1549621A1
(en)
*
|
2002-08-08 |
2005-07-06 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
|
CA2499497A1
(en)
|
2002-09-27 |
2004-04-08 |
Merck & Co., Inc. |
Substituted pyrimidines
|
AU2003303483A1
(en)
*
|
2002-12-23 |
2004-07-22 |
Millennium Pharmaceuticals, Inc. |
Ccr8 inhibitors
|
TW200510311A
(en)
*
|
2002-12-23 |
2005-03-16 |
Millennium Pharm Inc |
CCr8 inhibitors
|
US7491827B2
(en)
*
|
2002-12-23 |
2009-02-17 |
Millennium Pharmaceuticals, Inc. |
Aryl sulfonamides useful as inhibitors of chemokine receptor activity
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
WO2005037286A1
(en)
*
|
2003-03-25 |
2005-04-28 |
Vasopharm Biotech Gmbh |
Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
|
WO2005023242A1
(en)
|
2003-09-11 |
2005-03-17 |
Tibotec Pharmaceuticals Ltd. |
Entry inhibitors of the hiv virus
|
US20070105914A1
(en)
*
|
2003-09-18 |
2007-05-10 |
Armstrong Helen M |
Substituted sulfonamides
|
CN1902177A
(zh)
|
2003-09-22 |
2007-01-24 |
万有制药株式会社 |
新哌啶衍生物
|
US7223761B2
(en)
*
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
US20050250820A1
(en)
*
|
2004-03-08 |
2005-11-10 |
Amgen Inc. |
Therapeutic modulation of PPARgamma activity
|
WO2005097127A2
(en)
|
2004-04-02 |
2005-10-20 |
Merck & Co., Inc. |
Method of treating men with metabolic and anthropometric disorders
|
AU2005286592A1
(en)
*
|
2004-09-23 |
2006-03-30 |
Reddy Us Therapeutics, Inc. |
Novel pyrimidine compounds, process for their preparation and compositions containing them
|
EP2286837A3
(en)
|
2004-11-01 |
2013-09-04 |
Amylin Pharmaceuticals, LLC |
Treatment of obesity and obesity related diseases
|
US8394765B2
(en)
*
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
CA2587667A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Taisho Pharmaceutical Co., Ltd. |
Imine compound
|
EP1854787B1
(en)
*
|
2005-03-03 |
2010-09-01 |
Santen Pharmaceutical Co., Ltd. |
Novel cyclic compound having quinolylalkylthio group
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
US8138206B2
(en)
|
2005-05-30 |
2012-03-20 |
Msd. K.K. |
Piperidine derivative
|
CA2613678A1
(en)
|
2005-06-02 |
2006-12-07 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
US7923465B2
(en)
|
2005-06-02 |
2011-04-12 |
Glenmark Pharmaceuticals S.A. |
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
CA2618112A1
(en)
|
2005-08-10 |
2007-02-15 |
Banyu Pharmaceutical Co., Ltd. |
Pyridone compound
|
CA2617649A1
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
WO2007024004A1
(ja)
|
2005-08-24 |
2007-03-01 |
Banyu Pharmaceutical Co., Ltd. |
フェニルピリドン誘導体
|
US20090264426A1
(en)
|
2005-09-07 |
2009-10-22 |
Shunji Sakuraba |
Bicyclic aromatic substituted pyridone derivative
|
CA2624030A1
(en)
|
2005-09-29 |
2007-04-12 |
Tianying Jian |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
AU2006307046A1
(en)
|
2005-10-27 |
2007-05-03 |
Msd K.K. |
Novel benzoxathiin derivative
|
ES2381205T3
(es)
|
2005-11-10 |
2012-05-24 |
Msd K.K. |
Derivado espiro aza-sustituido
|
EP2081905B1
(en)
*
|
2006-07-28 |
2012-09-12 |
Boehringer Ingelheim International GmbH |
Sulfonyl compounds which modulate the cb2 receptor
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
EP2074084B1
(en)
*
|
2006-09-25 |
2013-08-28 |
Boehringer Ingelheim International GmbH |
Compounds which modulate the cb2 receptor
|
EP2072519A4
(en)
|
2006-09-28 |
2009-10-21 |
Banyu Pharma Co Ltd |
DIARYLKETIMINDERIVAT
|
WO2008098025A1
(en)
*
|
2007-02-08 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Arylsulfonamide compounds which modulate the cb2 receptor
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Msd株式会社 |
インドールジオン誘導体
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
EP2527360B1
(en)
|
2007-06-04 |
2015-10-28 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
WO2009061652A1
(en)
*
|
2007-11-07 |
2009-05-14 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the cb2 receptor
|
CN101939022A
(zh)
*
|
2007-11-14 |
2011-01-05 |
安米林药品公司 |
治疗肥胖以及肥胖相关疾病和病症的方法
|
AU2009220605A1
(en)
|
2008-03-06 |
2009-09-11 |
Msd K.K. |
Alkylaminopyridine derivative
|
JPWO2009119726A1
(ja)
|
2008-03-28 |
2011-07-28 |
Msd株式会社 |
メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
|
AU2009261248A1
(en)
|
2008-06-19 |
2009-12-23 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diarylketoxime derivative
|
JP5749162B2
(ja)
*
|
2008-07-10 |
2015-07-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cb2受容体を調節するスルホン化合物
|
WO2010013595A1
(ja)
|
2008-07-30 |
2010-02-04 |
萬有製薬株式会社 |
5員-5員又は5員-6員縮環シクロアルキルアミン誘導体
|
KR20110063485A
(ko)
*
|
2008-09-25 |
2011-06-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
Cb2 수용체를 선택적으로 조절하는 설포닐 화합물
|
AU2009307884B2
(en)
|
2008-10-22 |
2014-07-31 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2010051236A1
(en)
|
2008-10-30 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Isonicotinamide orexin receptor antagonists
|
CN102271509A
(zh)
|
2008-10-31 |
2011-12-07 |
默沙东公司 |
用于抗糖尿病药的新型环苯并咪唑衍生物
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
EP2379562A1
(en)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Bicyclic pyranone derivatives as nicotinic acid receptor agonists
|
EP2379076B1
(en)
|
2008-12-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Phosphodiesterase inhibitors and uses thereof
|
US8299103B2
(en)
|
2009-06-15 |
2012-10-30 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the CB2 receptor
|
JP5756800B2
(ja)
|
2009-06-16 |
2015-07-29 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cb2受容体を調節するアゼチジン2−カルボキサミド誘導体
|
US8383651B2
(en)
*
|
2009-09-22 |
2013-02-26 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the CB2 receptor
|
KR101735675B1
(ko)
|
2009-12-11 |
2017-05-15 |
오티포니 세라피틱스 리미티드 |
이미다졸리딘디온 유도체
|
US9315454B2
(en)
|
2010-01-15 |
2016-04-19 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the CB2 receptor
|
WO2011106273A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US8329735B2
(en)
|
2010-03-05 |
2012-12-11 |
Boehringer Ingelheim International Gmbh |
Tetrazole compounds which selectively modulate the CB2 receptor
|
WO2012012307A1
(en)
|
2010-07-22 |
2012-01-26 |
Boehringer Ingelheim International Gmbh |
Sulfonyl compounds which modulate the cb2 rece
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
BR112013021236B1
(pt)
|
2011-02-25 |
2021-05-25 |
Merck Sharp & Dohme Corp |
composto derivado de benzimidazol, e, composição
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
WO2014022528A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
AU2014219020A1
(en)
|
2013-02-22 |
2015-07-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
EP2803668A1
(en)
|
2013-05-17 |
2014-11-19 |
Boehringer Ingelheim International Gmbh |
Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
|
US10011637B2
(en)
|
2013-06-05 |
2018-07-03 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015054662A1
(en)
|
2013-10-10 |
2015-04-16 |
Eastern Virginia Medical School |
4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
|
AU2015308350B2
(en)
|
2014-08-29 |
2020-03-05 |
Tes Pharma S.R.L. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
US9585867B2
(en)
|
2015-08-06 |
2017-03-07 |
Charles Everett Ankner |
Cannabinod formulation for the sedation of a human or animal
|
CN109952292A
(zh)
|
2016-10-14 |
2019-06-28 |
Tes制药有限责任公司 |
α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
AR117122A1
(es)
|
2018-11-20 |
2021-07-14 |
Tes Pharma S R L |
INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
|
WO2020167706A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
WO2021026047A1
(en)
|
2019-08-08 |
2021-02-11 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
CN116249697A
(zh)
|
2020-08-18 |
2023-06-09 |
默沙东有限责任公司 |
二环庚烷吡咯烷食欲素受体激动剂
|